TL;DR
This study explored whether immune responses to common non-HIV vaccines (tetanus and hepatitis B) could predict immune responses to an HIV vaccine regimen (ALVAC-HIV and AIDSVAX B/E). They found moderate correlations, suggesting that these established vaccines might serve as useful baseline immunogenicity predictors in future HIV vaccine trials, potentially improving statistical power and efficiency.
What Problem Does This Paper Address?
Developing an effective HIV vaccine is a major global health challenge. A key hurdle in vaccine development is identifying "correlates of protection" (CoPs) – measurable immune responses that reliably predict whether a vaccine will prevent infection. If we could identify CoPs early in trials, it would allow for smaller, faster studies and more efficient vaccine refinement. However, directly measuring these CoPs in placebo recipients in efficacy trials is impossible. This paper addresses this by investigating whether immune responses to widely administered, non-HIV vaccines (tetanus toxoid - TT, and hepatitis B virus - HBV) could serve as "baseline immunogenicity predictors." The idea is that if these pre-existing or vaccine-induced responses correlate with the immune responses generated by an HIV vaccine, they could help predict the HIV vaccine's immunogenicity even before the HIV vaccine is administered. This is crucial for increasing the statistical power of vaccine efficacy trials and for assessing potential CoPs.
Methods
The researchers utilized data from the HVTN 097 trial, a phase 1b study that administered an HIV vaccine regimen (ALVAC-HIV and AIDSVAX B/E) alongside or in sequence with TT and/or HBV vaccines. They measured several types of immune responses:
- Intracellular Cytokine Staining (ICS): This flow cytometry technique was used to quantify CD4+ T-cell responses (specifically, the production of IFN-gamma and/or IL-2) to TT and HBV antigens.
- Binding Antibody Multiplex Assay (BAMA): This assay measured IgG-binding antibody responses to TT and HBV antigens in serum.
- HIV Vaccine-Induced Immune Responses: They also measured various immune responses to the ALVAC-HIV and AIDSVAX B/E HIV vaccine regimen, including IgG-binding antibodies, IgA-binding antibodies, Antibody-Dependent Cellular Cytotoxicity (ADCC), Antibody-Dependent Cellular Phagocytosis (ADCP), and CD4+ T-cell responses.
The core of their analysis involved correlating the peak immune responses to the TT and HBV vaccines with the peak immune responses elicited by the HIV vaccine regimen. They employed Spearman's rank correlations and adjusted for multiple comparisons using the False Discovery Rate (FDR) method, setting a significance threshold of FDR ≤ 0.2.
Datasets
The study used data collected from participants in the HVTN 097 clinical trial. This trial enrolled 100 participants in South Africa and involved different vaccination arms receiving either TT, HBV, the HIV vaccine regimen, or placebo. The immune response data collected from these participants served as the dataset for the analysis. No new benchmarks or datasets were introduced.
Key Insights and Ideas
- Cross-Vaccine Immunogenicity Prediction: The most significant insight is that immune responses to established, non-HIV vaccines (TT and HBV) can indeed correlate with immune responses generated by an HIV vaccine. This provides a proof-of-concept for using these common vaccines as potential baseline predictors.
- Moderate but Meaningful Correlations: While the correlations found were moderate (rho values around 0.34-0.37), they were statistically significant after FDR correction. This suggests that these non-HIV vaccine responses are not just random noise but carry some predictive information about the HIV vaccine response.
- TT as a Stronger Predictor: Three out of the four significant correlations involved TT-induced responses, particularly IgG-binding antibodies, predicting HIV vaccine responses. This highlights TT as a potentially more robust predictor compared to HBV in this specific context.
- Implications for Trial Design: The findings suggest that incorporating measurements of TT or HBV responses could enhance the statistical power of future HIV vaccine efficacy trials, potentially allowing for smaller sample sizes or shorter study durations.
Key Results
The study identified four statistically significant correlations (FDR ≤ 0.2) between non-HIV vaccine-induced immune responses and HIV vaccine-induced immune responses:
- TT IgG antibodies predicting HIV IgG antibodies: A moderate correlation (rho = 0.368, FDR = 0.137) was found between TT-specific IgG-binding antibody responses (measured one month after TT vaccination) and IgG-binding antibody responses to the MN gp120 gDneg antigen of the HIV vaccine (measured two weeks after the second ALVAC-HIV and AIDSVAX B/E boost).
- TT IgG antibodies predicting HIV IgG antibodies: Another significant correlation (rho = 0.340, FDR = 0.137) was observed between TT-specific IgG-binding antibody responses and IgG-binding antibody responses to the A244 D11gp120a antigen of the HIV vaccine.
- HBV CD4+ T-cells predicting HIV IgG antibodies: A significant correlation (rho = 0.361, FDR = 0.137) was found between HBV-specific CD4+ T-cell responses (measured two weeks after the third HBV vaccination) and IgG-binding antibody responses to the gp70BCaseAV1V2 antigen of the HIV vaccine (measured two weeks after the second ALVAC-HIV and AIDSVAX B/E boost).
- TT IgG antibodies predicting HIV ADCP: A correlation (rho = 0.357, FDR = 0.119) was observed between TT-specific IgG-binding antibody responses and ADCP scores against C Env gp140.
Other assessed correlations between non-HIV vaccine responses and HIV vaccine responses (including IgA, ADCC, and CD4+ T-cell responses) were not found to be significant.
Limitations and Future Work
The authors acknowledge several limitations:
- Generalizability: The moderate correlations observed might not be universal and could vary across different populations due to factors like age, genetics, and environmental influences.
- Vaccine Regimen Specificity: The study used a specific HIV vaccine regimen (ALVAC-HIV and AIDSVAX B/E) and a particular prime-boost strategy. It's unclear if these correlations would hold for different HIV vaccine platforms or regimens.
- Correlates of Risk Focus: The study focused on immune responses previously identified as correlates of risk for HIV acquisition. Different correlates might be relevant for other vaccine regimens.
- Global Coverage: While TT and HBV vaccines have high global coverage, they might not be the "most optimal" choices for baseline predictors if immune responses wane significantly. However, they could still be suitable depending on regional coverage and timing.
Future work could involve:
- Verification in other trials: Confirming these correlations in other HIV vaccine trials with different regimens and populations.
- Investigating other non-HIV vaccines: Exploring other commonly administered vaccines as potential predictors.
- Timing of HBV vaccination: Given that HBV vaccination occurred after the HIV vaccine in this trial, future studies could investigate the predictive value of HBV responses when administered before the HIV vaccine.
- Exploring other immune response types: Expanding the analysis to include a broader range of immune responses.
Summary updated